Advertisement

memo - Magazine of European Medical Oncology

, Volume 6, Issue 4, pp 258–261 | Cite as

The contribution of antibodies to targeted cancer therapy

  • Panagiotis Apostolou
  • Ioannis PapasotiriouEmail author
short review

Abstract

The fight against cancer is the focus of many research groups, as it is classified as one of the leading causes of death. The treatment of cancer is mainly composed of surgery, chemotherapy, radiation therapy, immunotherapy, and nowadays through targeted therapy as well. Targeted therapy targets the molecules whose expression correlates to carcinogenesis. It can be performed either with small molecule drugs or with monoclonal antibodies. Based on the capacity of the monoclonal antibodies to recognize a certain epitope of an antigen, and the fact that cancer cells express many antigens compared with normal (noncancer) cells abnormally in their surface, cytotoxicity may be induced directly in these cells. The cytotoxicity can be caused either via antibody-dependent cellular interaction or via the complement system. The possibility to create monoclonal antibodies against any antigen led to production of new medicines, many of which are already in clinical use. The ability to conjugate several molecules to antibodies also made the delivery of drugs/substances directly to cancer cells possible, thereby reducing the side effects of cancer treatment. This review presents the implementation of antibodies to targeted therapy, emphasizing the antibody-dependent cytotoxicity, as well as the monoclonal antibodies that are used in cancer treatment.

Keywords

Targeted therapy Monoclonal antibodies Antibody-dependent cellular cytotoxicity 

Notes

Conflict of interest

The authors declare that there is no conflict of interest.

References

  1. 1.
    Joensuu H. Novel cancer therapies: more efficacy, less toxicity and improved organ preservation. Ann Med. 2000 Feb;32(1):31–3.Google Scholar
  2. 2.
    Sawyers C. Targeted cancer therapy. Nature. 2004 Nov 18;432(7015):294–7.Google Scholar
  3. 3.
    Katzel JA, Fanucchi MP, Li Z. Recent advances of novel targeted therapy in non-small cell lung cancer. J Hematol Oncol. 2009;2:2.Google Scholar
  4. 4.
    Bamias A, Dimopoulos MA. Thalidomide and immunomodulatory drugs in the treatment of cancer. Expert Opin Investig Drugs. 2005 Jan;14(1):45–55.Google Scholar
  5. 5.
    Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012 Apr;12(4):278–87.Google Scholar
  6. 6.
    Waldmann TA. Monoclonal antibodies in diagnosis and therapy. Science. 1991 Jun 21;252(5013):1657–62.Google Scholar
  7. 7.
    Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000 Apr;6(4):443–6.Google Scholar
  8. 8.
    Prang N, Preithner S, Brischwein K, Goster P, Woppel A, Muller J, et al. Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines. Br J Cancer. 2005 Jan 31;92(2):342–9.Google Scholar
  9. 9.
    Janeway CA Jr, Travers P, Walport M, et al. Immunobiology: the immune system in health and disease,. 5th edn. New York: Garland Science; 2001.Google Scholar
  10. 10.
    Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol. 2006 Apr;6(4):295–307.Google Scholar
  11. 11.
    Chawla-Sarkar M, Lindner DJ, Liu YF, Williams BR, Sen GC, Silverman RH, et al. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis. 2003 Jun;8(3):237–49.Google Scholar
  12. 12.
    Stone KD, Prussin C, Metcalfe DD. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol. 2010 Feb;125(2 Suppl 2):73–80.Google Scholar
  13. 13.
    Negri FV, Musolino A, Naldi N, Bortesi B, Missale G, Laccabue D, et al. Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy. Pharmacogenomics J. 2013 Jan 8. doi: 10.1038/tpj.2012.54. (Epub ahead of print)Google Scholar
  14. 14.
    Hudis CA. Trastuzumab–mechanism of action and use in clinical practice. N Engl J Med. 2007 Jul 5;357(1):39–51.Google Scholar
  15. 15.
    Blumenthal GM, Scher NS, Cortazar P, Chattopadhyay S, Tang S, Song P, et al. First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer. Clin Cancer Res. 2013 Sep 15;19(18):4911–6.Google Scholar
  16. 16.
    Thomas DA, O’Brien S, Kantarjian HM. Monoclonal antibody therapy with rituximab for acute lymphoblastic leukemia. Hematol Oncol Clin North Am. 2009 Oct;23(5):949–71, v.Google Scholar
  17. 17.
    Mossner E, Brunker P, Moser S, Puntener U, Schmidt C, Herter S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood. 2010 Jun 3;115(22):4393–402.Google Scholar
  18. 18.
    Iida S, Kuni-Kamochi R, Mori K, Misaka H, Inoue M, Okazaki A, et al. Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood. BMC Cancer. 2009;9:58.Google Scholar
  19. 19.
    Gancz D, Fishelson Z. Cancer resistance to complement-dependent cytotoxicity (CDC): Problem-oriented research and development. Mol Immunol. 2009 Sep;46(14):2794–800.Google Scholar
  20. 20.
    Askew D, Chu RS, Krieg AM, Harding CV. CpG DNA induces maturation of dendritic cells with distinct effects on nascent and recycling MHC-II antigen-processing mechanisms. J Immunol. 2000 Dec 15;165(12):6889–95.Google Scholar
  21. 21.
    Friedberg JW. Unique toxicities and resistance mechanisms associated with monoclonal antibody therapy. Hematology Am Soc Hematol Educ Program. 2005:329–34.Google Scholar
  22. 22.
    Waldmann TA. Immunotherapy: past, present and future. Nat Med. 2003 Mar;9(3):269–77.Google Scholar
  23. 23.
    Sliwkowski MX, Mellman I. Antibody therapeutics in cancer. Science. 2013 Sep 13;341(6151):1192–8.Google Scholar
  24. 24.
    Zhang B. Ofatumumab. MAbs. 2009 Jul-Aug;1(4):326–31.Google Scholar
  25. 25.
    Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Smith J, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol. 2008 Oct 20;26(30):4875–82.Google Scholar
  26. 26.
    Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun. 2005 Jul 29;333(2):328–35.Google Scholar
  27. 27.
    Tarhini AA, Iqbal F. CTLA-4 blockade: therapeutic potential in cancer treatments. Onco Targets Ther. 2010;3:15–25.Google Scholar
  28. 28.
    Prieto PA, Yang JC, Sherry RM, Hughes MS,Kammula US, White DE, et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res. 2012 Apr 1;18(7):2039–47.Google Scholar
  29. 29.
    Suarez N, Alfaro C, Dubrot J, Palazon A, Bolanos E, Erro L, et al. Synergistic effects of CTLA-4 blockade with tremelimumab and elimination of regulatory T lymphocytes in vitro and in vivo. Int J Cancer. 2011 Jul 15;129(2):374–86.Google Scholar
  30. 30.
    Luque I, Reyburn H, Strominger JL. Expression of the CD80 and CD86 molecules enhances cytotoxicity by human natural killer cells. Hum Immunol. 2000 Aug;61(8):721–8.Google Scholar
  31. 31.
    Chames P, Baty D. Bispecific antibodies for cancer therapy: the light at the end of the tunnel? MAbs. 2009 Nov-Dec;1(6):539–47.Google Scholar
  32. 32.
    Linke R, Klein A, Seimetz D. Catumaxomab: clinical development and future directions. MAbs. 2010 Mar-Apr;2(2):129–36.Google Scholar
  33. 33.
    Pescovitz MD. Daclizumab: humanized monoclonal antibody to the interleukin-2 receptor. Expert Rev Clin Immunol. 2005 Sep;1(3):337–44.Google Scholar
  34. 34.
    Both L, Banyard AC, van Dolleweerd C, Wright E, Ma JK, Fooks AR. Monoclonal antibodies for prophylactic and therapeutic use against viral infections. Vaccine. 2013 Mar 15;31(12):1553–9.Google Scholar
  35. 35.
    Balaian L, Ball ED. Anti-CD33 monoclonal antibodies enhance the cytotoxic effects of cytosine arabinoside and idarubicin on acute myeloid leukemia cells through similarities in their signaling pathways. Exp Hematol. 2005 Feb;33(2):199–211.Google Scholar
  36. 36.
    Silacci M, Brack SS, Spath N, Buck A, Hillinger S, Arni S, et al. Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors in vivo. Protein Eng Des Sel. 2006 Oct;19(10):471–8.Google Scholar
  37. 37.
    Murakami H, Doi T, Yamamoto N, Watanabe J, Boku N, Fuse N, et al. Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2012 Sep;70(3):407–14.Google Scholar

Copyright information

© Springer-Verlag Wien 2013

Authors and Affiliations

  1. 1.Research Genetic Cancer Centre Ltd (R.G.C.C. Ltd)FilotasGreece

Personalised recommendations